|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400089797 |
|
最近更新日期: Date of Last Refreshed on: |
2024-09-14 17:08:23 |
|
注册时间: Date of Registration: |
2024-09-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
不同减重饮食在减重早期对尿酸水平及痛风发作的影响 |
|
Public title: |
Effects of different weight-loss diets on uric acid levels in the early stages of weight loss |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
不同减重饮食在减重早期对尿酸水平及痛风发作的影响 |
|
Scientific title: |
Effects of different weight-loss diets on uric acid levels and gout attacks in the early stages of weight loss |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘爽 |
研究负责人: |
陈海冰 |
|
Applicant: |
Shuang Liu |
Study leader: |
Haibing Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 198 2179 3268 |
研究负责人电话: Study leader's telephone: |
+86 189 3017 3813 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liushuang08@126.com |
研究负责人电子邮件: Study leader's E-mail: |
hbchen@tongji.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区延长中路301号 |
研究负责人通讯地址: |
上海市静安区延长中路301号 |
|
Applicant address: |
No.301, Yanchang Middle Road, Jing'an District, Shanghai |
Study leader's address: |
No.301, Yanchang Middle Road, Jing'an District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第十人民医院 |
||
|
Applicant's institution: |
Shanghai Tenth People's Hospital |
||
|
研究负责人所在单位: |
上海市第十人民医院 |
||
|
Affiliation of the Leader: |
Shanghai Tenth People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SHSY-IEC-5.0/24KY26/P01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市第十人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Tenth People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-09-13 00:00:00 |
||
|
伦理委员会联系人: |
余飞 |
||
|
Contact Name of the ethic committee: |
Fei Yu |
||
|
伦理委员会联系地址: |
上海市静安区延长中路301号 |
||
|
Contact Address of the ethic committee: |
No. 301 Yanchang Middle Road, Jing'an District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 198 2179 3268 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
liushuang08@126.com |
|
研究实施负责(组长)单位: |
上海市第十人民医院内分泌科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Endocrinology, Shanghai Tenth People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市静安区延长中路301号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 301 Yanchang Middle Road, Jing'an District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self fund |
||||||||||||||||||||||
|
Target disease: |
Hyperuricemia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本课题拟通过评估几种不同减重饮食对超重和肥胖高尿酸血症患者短期带来的影响,包括对血尿酸水平和痛风发作的影响评估,找到最佳减重饮食方式以避免减重初期血尿酸升高和痛风发作,并探讨减重早期尿酸水平升高和诱发痛风发作的影响因素,为后续的减重过程中高尿酸血症和痛风发作的预防提供干预靶点。 |
||||||||||||||||||||||
|
Objectives of Study: |
This project aims to find the best weight-loss diet to avoid elevated blood uric acid and gout attacks in the early stage of weight loss by evaluating the benefits and harms of several different weight-loss diets on overweight and obese hyperuricemia patients in the short term (one month before), including the evaluation of the impact on blood uric acid levels and gout attacks, and to explore the influencing factors of elevated uric acid levels and gout attacks in the early stages of weight loss, so as to provide intervention targets for the prevention of hyperuricemia and gout attacks in the subsequent weight loss process. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)18-65周岁的男性; 2)诊断高尿酸血症者,指正常嘌呤饮食状态下,非同日两次 空腹检测血尿酸>420μmol/L(7mg/dl) 3)BMI≥25.0 kg/m2; |
||||||||||||||||||||||
|
Inclusion criteria |
1) Male aged 18-65; 2) Patients diagnosed with hyperuricemia refer to the fasting test of blood uric acid > 420 μmol/L (7 mg/dl) twice on the same day under normal purine diet 3)BMI≥25.0 kg/m2; |
||||||||||||||||||||||
|
排除标准: |
?1)入组前2周内使用可能影响尿酸的药物,包括:苯溴马隆、别嘌呤醇、非布司他等; 2)入组前2周内有痛风发作; 3)严重肝功能不全或肾脏疾病(AST 或 ALT>正常上限的 3 倍,或eGFR<30ml/min/1.73 m2); 4)存在影响糖脂代谢的其他疾病:糖尿病、甲状腺功能亢进症、甲状腺功能减退症、皮质醇增多症等; 5)如合并应用其他药物,需入组前三个月保持药物剂量稳定; 6)继发疾病或药物导致的肥胖; 7)患有严重的胃肠道疾病患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
?1) Use of drugs that may affect uric acid within 2 weeks before enrollment, including: benzbromarone, allopurinol, febuxostat, etc.; 2) Gout attack within 2 weeks prior to enrollment; 3) severe hepatic insufficiency or renal disease (AST or ALT> 3 times the upper limit of normal, or eGFR <30ml/min/1.73 m2); 4) Other diseases that affect glucose and lipid metabolism: diabetes, hyperthyroidism, hypothyroidism, hypercortisolism, etc.; 5) If other drugs are used in combination, the drug dose should be kept stable for three months before enrollment; 6) obesity caused by secondary diseases or medications; 7) Patients with severe gastrointestinal diseases; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-14 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-09-14 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
使用SAS统计软件进行区组随机化,将符合条件的受试者分成34个大小相等的区组,每个区组长度为3。将每一个区块内部的受试者按1:1:1的分配比例随机分配到三组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Blocks were randomized using SAS statistical software, and eligible subjects were divided into 34 equally sized blocks, each with a length of 3. Subjects within each block were randomly assigned to three groups in a 1:1:1 allocation ratio. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |